Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The evolving experience using everolimus in clinical transplantation.

R N Formica1, K M Lorber, A L Friedman

  • 1Department of Internal Medicine, Section of Nephrology, Yale University School of Medicine, New Haven, CT 06520, USA.

Transplantation Proceedings
|March 26, 2004
PubMed
Summary

Everolimus, a novel TOR inhibitor, offers enhanced immunosuppression options for organ transplant patients. It effectively inhibits cell proliferation with manageable side effects like hyperlipidemia and reduced nephrotoxicity when combined with lower cyclosporine doses.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optical polarization of excitons and trions under continuous and pulsed excitation in single layers of WSe<sub>2</sub>.

Nanoscale·2017
Same author

Optical polarization and intervalley scattering in single layers of MoS2 and MoSe2.

Scientific reports·2016
Same author

Anomalous temperature-dependent spin-valley polarization in monolayer WS2.

Scientific reports·2016
Same author

Spin transport and Hanle effect in silicon nanowires using graphene tunnel barriers.

Nature communications·2015
Same author

Vascular management during live donor nephrectomy: an online survey among transplant surgeons.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2015
Same author

Spontaneous resolution of acute rejection and tolerance induction with IL-2 fusion protein in vascularized composite allotransplantation.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2015

Area of Science:

  • Immunology
  • Pharmacology
  • Transplantation Medicine

Background:

  • Everolimus is a sirolimus derivative and a potent inhibitor of cell proliferation.
  • It targets the target of rapamycin (TOR) pathway, inducing cell cycle arrest.
  • Sirolimus and everolimus share a similar mechanism of action.

Purpose of the Study:

  • To evaluate the safety and efficacy of everolimus in organ transplantation.
  • To compare everolimus with sirolimus regarding pharmacokinetic properties and side effects.
  • To explore the potential of everolimus in combination therapy for immunosuppression.

Main Methods:

  • Large-scale, blinded, randomized, international clinical trials in renal and cardiac transplantation.
  • Pharmacokinetic analysis comparing everolimus and sirolimus.

Related Experiment Videos

  • Assessment of side effects including hyperlipidemia and nephrotoxicity.

    • Main Results:

    • Everolimus demonstrated potent inhibition of cell proliferation.
    • It has improved pharmacokinetic properties over sirolimus, including higher bioavailability.
    • Combination therapy with reduced cyclosporine doses showed controlled hyperlipidemia and reduced nephrotoxicity with low acute rejection rates.

    Conclusions:

    • Everolimus represents a promising new option for immunosuppression in organ transplantation.
    • Its favorable side effect profile, especially in combination therapy, enhances its therapeutic potential.
    • Everolimus may reduce intimal expansion in cardiac transplant recipients, suggesting benefits for vascular health.